Moreover, case reports indicate that IFN treatment can be marginal against flavivirus diseases and this is confounded by individuals who are immuno-compromised or those who delay or cannot readily access medical care [34–37]. This evidence concerns the gene IFNA1 and glycogen storage disease VI.